Medical Center - University of Freiburg, Germany
Freiburg im Breisgau, 79106, Germany
Location status: Recruiting
NCT Number: NCT06711731
Spinal CSF leaks are considered as rare disease. They cause a variety of symptoms, mainly culminating in a chronic headache syndrome. Crucially, yet often disregarded, the disease holds the potential for cure. The multitude of symptoms, and their inconsistency over time are just two of many challenges preventing timely diagnosis and treatment in many patients.
Spinal CSF leaks can occur after intentional or accidental dural puncture (post-dural puncture headache - PDPH) or spontaneously (spontaneous intracranial hypotension - SIH). Awareness is steadily increasing with simultaneous increase of recognized patients. Yet, research and diagnostic is mainly provided by few specialized centers, as e.g. Freiburg. Thus, many observations point towards a large non-diagnosed and non-recognized number of patients, most likely being misdiagnosed and mistreated.
Objective: The aim of the registry is to collect structured information on the frequency, cause, symptoms, diagnostic procedures, treatment options and long-term outcome. With the help of the registry, we would like to contribute to a better understanding and treatment of the diseases.
Methods: Prospective, longitudinal registry on patients with suspected SIH or PDPH, including data on demographics, clinical presentation, diagnostic findings, treatment, at treatment outcome.
Interested in participating?
Request InfoAll sexes
Observational
Freiburg im Breisgau, 79106, Germany
Location status: Recruiting
Spinal CSF leaks have a severe impact on quality of life and health. Symptoms vary from chronic headache syndrome to intracranial bleeding, cognitive decline, and coma. Crucially, yet often disregarded, the disease holds the potential for cure.
Lumbar dural leaks can arise from commonly performed medical interventions such as diagnostic lumbar punctures, spinal anesthesia, spinal infiltrations, or incidental dural punctures during epidural analgesia in obstetric care, resulting in post-dural puncture headache (PDPH).
Additionally, a notable fraction of spinal CSF leaks manifests as spontaneous intracranial hypotension (SIH), which derives from different types of spontaneous leaks along the Spine and remains broadly under-recognized.
The main clinical symptoms of spinal CSF leaks are orthostatic headaches with a most often defined beginning, typically accompanied by hearing impairment and dizziness, worsened by exercise and movement. Additionally, other manifestations are known, such as cognitive decline, bilateral brachial amyotrophy, paradox headache, fatigue, and many more. In patients presenting with spinal CSF leaks, the accurate diagnosis often eludes clinicians, leading to frequent misdiagnoses of chronic migraine, fatigue, or psychiatric conditions. Many patients endure months, if not years, before a diagnosis of a treatable condition is finally established. The heterogeneity of the symptoms can appear inconsistent or even paradoxical, posing diagnostic challenges. The extent of possible long-term deterioration is not recognized.
The reported incidence of PDPH fluctuates considerably, ranging from 2 to 40 per 100 procedures performed. This variance is influenced by patient-related factors (e.g., age, gender, pregnancy status) and procedural factors (e.g., needle size and type). PDPH, according to current criteria, occurs within 5 days after a dural puncture. Nevertheless, there are widely underestimated pitfalls: a dural puncture is not always recognized by the person performing an epidural procedure, symptoms can occur after more than 5 days, and disease courses can be chronic. These facts are widely unknown, leading to largely hidden figures of patients being under or misdiagnosed and, thus, not treated. Moreover, PDPH is primarily observed following unintentional dural puncture during the administration of obstetric anaesthesia and analgesia to parturients.
Spontaneous intracranial hypotension (SIH) can be caused by ventral, lateral, or sacral spinal leaks or by CSF-venous fistulae, which was first described in 2014. An annual incidence rate of ~ 4/100,000 was estimated in 2022. This rate is likely underestimated as it only includes confirmed cases, thus recognized cases within a widely non-recognized entity. Often, patients are neither identified nor directed to the appropriate MRI, which, in numerous instances, could lead to the correct diagnosis. Even when SIH is identified, non-targeted epidural blood patches in the lumbar region are often not administered due to perceived elevated risks. An epidural blood patch might be able to help to heal the leak. At the same time, it must be noted that even long-term improvement does not necessarily indicate closure of the leak and prevention of long-term sequelae, such as superficial siderosis. Invasive diagnostics are not employed to pinpoint the location, and treatment to seal the leak is not consistently pursued. The effects of treatment are often immediate and can be successful even in chronic patients. Evidence shows that leaks are held open by new membranes (Neo-membranes) that prevent spontaneous healing. Thus, the correct localization of such a leak and targeted sealing or close follow-ups should be initiated.
The management approaches for SIH and PDPH significantly deviate from standard pain management strategies employed for other types of headaches. Noteworthy interventions include the application of blood patches and even surgical measures to seal the leak, offering curative solutions. Those enduring chronic spinal CSF leaks experience profound limitations in their health-related quality of life, comparable to those with chronic immunological diseases or cancer. Overlooking the diagnosis and management of spinal CSF leaks may precipitate progressive deterioration, with the potential for persistent sequelae like superficial siderosis, syndromes mimicking frontotemporal dementia (FTD), and chronic subdural hematoma formation.
This registry aims to set ground for standardized, prospective demographic, diagnostic and treatment data assessments, and patient self-reported outcome measures.
Collecting this data is essential to potentially exploring risk factors, understanding outcome predictors, and refining diagnostics. Additionally, standardized data collection will allow the appropriate designing of urgently needed randomized trials.
Aims:
Primary aim:
To describe the proportion of patients diagnosed with SIH or PDPH
Secondary aims:
Method:
The registry is prospective, longitudinal and currently monocentric*. Diagnostic, treatment, and follow-up procedures follow clinical standard operating procedures (SOP) according to the suspected diagnosis and the clinical findings.
Routinely assessed data of the initial diagnostic workup and the individual's disease course with or without treatment will be collected over 2 years per individual. The investigators' semi-annual meetings ensure the achievement of the register's predefined aims.
There are no specific risks or benefits for the patients participating in this registry. Any procedure will be performed according to clinical standards as indicated. There will be no additional visits to the hospital or the ambulatory. There will be no additional imaging performed, especially no additional radiation.
A merely intrinsic benefit might exist for the patient supporting this study and supporting medical research.
As this is an explorative and observational study on rare diseases without formal sample size estimation, we limit the study by time of duration (10 years).
Patients suffering from rare diseases most often face delays in diagnostics and treatments. To underscore this known burden: By an estimated population of 1.74 Mio in the Freiburg area and an incidence rate of SIH of about 5/100.0004, approximately 85 patients should be expected per year stemming from this area. Freiburg is the only center offering adequate diagnostic pipelines for these patients. Despite the increasing awareness, the number of patients diagnosed in the area adjunct to the Freiburg CSF center is within a range of 15 to 20 patients per year, thus still too low compared to the expected number with many patients unrecognized, and or underdiagnosed.
Our current numbers of confirmed SIH treatments range from 100 per year with patients being referred throughout Germany and about 15-20 international patients per year. We expect this rate to rise within the next few years. The number of PDPH patients with a focus on persistent PDPH patients is currently rapidly increasing. We see about 40-60 per year.
Interim-Evaluation of the Registry's primary and secondary descriptive aims will be performed and reported as a step-wise, dynamic approach:
The secondary objectives, which involve comparisons, the exploration of diagnostic markers, and risk factors, will be addressed using a dynamic biostatistical model: The analysis will only be conducted after a power analysis deems the observed sample adequate.
Proportions will be presented as a percentage with 95% confidence interval (CI).
The sata of patients with different types of spinal CSF leaks will be summarized using descriptive statistics, i.e. median and quartiles for continuous and absolute and relative frequencies for categorical variables, regarding their clinical, laboratory, and diagnostic findings, and number of diagnostic and therapeutic procedures needed.
Furthermore, the proportion of SIH patients with different spinal CSF leak types
Age, sex, BMI, clinical presentation, and diagnostic findings between different spinal CSF leaks will be compared using the Mann-Whitney-Wilcoxon test and Chi2 test for continuous and categorical variables, respectively.
A multivariable logistic regression for the presence of SIH, PDPH, and chronic PDPH, respectively, will be constructed using the clinical and diagnostic parameters with some evidence for a difference according to the presence of a spinal CSF leak (p < 0.2). The potential nonlinearity of the age effect is evaluated based on a residual analysis of the regression model. Odds ratios with 95% CI will be reported. Using bootstrapping, we will present a ROC curve and AUC with 95% Due to the exploratory approach,, no correction for multiple testing will be performed.
A multivariable linear regression for imaging findings (especially Bern Score, presence of SLEC, vand olumetries), and for the patient-reported outcomes will be constructed using the clinical and diagnostic parameters at admission with some evidence for a difference (p<0.2). Adjusted R-squares, Beta-coefficients with 95% CI, standard errors will be reported.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
a) Symptoms beeing conclusively explained by another known diagnosis
Time frame: up to 4 weeks after inclusion
Time frame: at time of inclusion
Number of patient with suspicion for SIH work-up/year
Time frame: at time of inclusion
Country, City
Time frame: at time of inclusion
Medical SIH treatment, Other symptomatic treatment, Untargeted lumbar blood patch, Targeted blood patch, Targeted fibrin patch, Endovascular embolization, Minimally invasive surgery, Open surgery - dorsal approach, Open surgery-ventral approach, Open surgery-transforaminal approach, Discectomy, Laminectomy, Stabilization procedures, Surgery, other techniques
Time frame: at time of inclusion
years
Time frame: at time of inclusion
male female diverse
Time frame: at time of inclusion
height in meter (m)
Time frame: at time of inclusion
kilogram (kg)
Time frame: at time of inclusion
range in 0-6, 0 indicating best health
Time frame: at time of inclusion
Neurological deficits due to previously attempted treatments at the time of inclusion
Time frame: at time of inclusion
descriptive
Time frame: at time of inclusion
range 0-30, 30 indicating best performance
Time frame: at time of inclusion
in minutes needed to fulfill the task
Time frame: at time of inclusion
kg/m^2
Time frame: at time of inclusion
Nicotine, Alcohol, Recreational drugs
Time frame: at time of inclusion
Headache-Impact-Test (HIT)-6 range 36 to 78 points, 78 indicating highest impact of headaches.
Time frame: at time of inclusion
<0 to 1, with 1 indicating unimpaired health
Time frame: at time of inclusion
13-item Self-Adminestered Comorbidity Questionaire (SCQ), range 0 to 39, 0 indicating lowest burden
Time frame: at time of inclusion
range 7 - 42, 7 indicating highest improvement
Time frame: up to 4 weeks
cmH2O
Time frame: up to 4 weeks
range 0 to 9 with 9 indicating highest likelihood of a spinal CSF leak
Time frame: up to 4 weeks
Meningeal enhancement (yes/no), Subdural fluid (yes/no), Venous Distention (yes/no), Effaced suprasellar distance (yes/no), Effaced mamillopontine distance (yes/no), Effaced prepontine distance (yes/no)
Time frame: up to 4 weeks
(yes/no)
Time frame: up to 4 weeks
(yes/no)
Time frame: up to 4 weeks
(yes/no)
Time frame: up to 4 weeks
mm^3
Time frame: up to 4 weeks
mm^3
Time frame: up to 4 weeks
Density scores of the intracranial compartments MRI head & spine
Time frame: at primary workup
Sievert
Time frame: up to 24 weeks
Number of myelographies performed for precise localization
Time frame: up to 4 weeks
conventional,digital subtraction, dynamic CT, Cone-beam CT, Photon-counting CT, fluoroscopy, Other (specify)
Time frame: up to 4 weeks
nausea, dizziness/vertigo, emesis, allergic reaction, seizure, treatment intensive care unit (independent of cause))
Time frame: up to 4 weeks
in 0-10, 10 numeric rating scale
Time frame: up to 4 weeks
prone, lateral decubitus, supine
Time frame: up to 4 weeks
resisted insipration, pressuization, valsalva maneuver
Time frame: up to 4 weeks
pressure (mmHg)
Time frame: up to 4 Weeks
mmHg/(ml/min)
Time frame: up to 4 weeks
Elastance coefficient (1/ml)
Time frame: up to 4 weeks
ml
Time frame: up to 4 weeks
Time frame: up to 4 weeks
Time frame: up tp 4 weeks
half-life of the tracer in the CSF space (minutes)
Time frame: up to 4 weeks after inclusion
Time frame: up to 4 weeks
Time frame: up to 4 weeks
Time frame: up to 4 weeks
Time frame: up to 4 weeks
Time frame: up to 4 weeks
Time frame: up to 4 weeks
month
Time frame: up to 4 weeks
Untargeted lumbar blood patch, Targeted blood patch, Targeted fibrin patch, Endovascular embolization, Minimally invasive surgery with patching, Minimally invasive surgery with clipping, Minimally invasive surgery with disconnection, Open surgery, dorsal approach, Open surgery, ventral approach, Open surgery, transforaminal approach, Surgery, other techniques, Medical PDPH treatment, Other symptomatic treatment, e.g. infiltration N. occipitalis, Untargeted lumbar platelet-rich fibrin patch
Time frame: up to 4 weeks or longer, depending on the number of surgeries
in numbers of SIH/PDPH-surgeries/year
Time frame: up to 4 weeks
Twist drill craniostomy (yes/no), Burr hole craniostomy (yes/no ), Mini craniotomy (yes/no), Conventional trepanation (yes/no), Use of drains and any form of controlled lavage (saline and or clot lysis) (yes/no,), Embolization of MMA (middle meningeal arteria) (yes/no), Other intervention (yes/no)
Time frame: up to 4 weeks
date
Time frame: up to 4 weeks
Time frame: up to 4 weeks
Rebound hypertension, Persistence/Reoccurrence of the leak, Suture insufficiency, Infect (systemic/local), Bleeding, Sensory deficits, Motor deficits, Gait ataxia, Bladder dysfunction, Bowl dysfunction, Others
Time frame: up to 4 weeks
Time frame: up to 4 weeks
"location truly known"
Time frame: up to 4 weeks
days
Time frame: up to 4 weeks
days
Time frame: up to 4 weeks
Time frame: up to 4 weeks
Fluids, Caffeine, Bedrest, Medical treatment, Other treatment, e.g., infiltrations, Untargeted lumbar bloodpatch, Surgery
Time frame: up to 4 weeks
(yes/no)
Time frame: up to 4 weeks
Time frame: up to 4 weeks
ventral post-dural puncture leak, dorsal post-dural puncture pseudomeningocele ("arachnoid bleb"), dorsal post-dural puncture leak None
Time frame: up to 4 weeks
neo-membranes (pseudo dura), webs, funnels
Time frame: at time of inclusion
Time frame: up to 4 weeks
Time frame: up to 4 weeks
ventral post-dural puncture leak, dorsal post-dural puncture pseudomeningocele ("arachnoid bleb"), dorsal post-dural puncture leak, None
Time frame: uo to 4 weeks
CT Head, MRI head, MRI spine, Dynamic digital subtraction myelogram, Dynamic CT-myelogram, Photon-counting CT-myelogram, Cone-beam myelogram, Infusion testing, PET-CT, Other (to exclude/confirm alternative diagnosis)
Time frame: up to 4 weeks
ml
Time frame: at time of inclusion
range 0 to 5, 0 indicating full capacity
Time frame: at time of inclusion
Time frame: at time of inclusion
range 0 to 10, 10 indicating most severe pain
Time frame: at time of inclusion
Time frame: at time of inclusion
hours
Time frame: at time of inclusion
Time frame: at time of inclusion
Time frame: at time of inclusion
Time frame: at time of inclusion
Time frame: at time of inclusion
Time frame: at time of inclusion
Time frame: at time of inclusion
rated between 0 to 5, with 5 indicating highest burden
Time frame: up to 4 weeks
Time frame: up to 4 weeks
number of TICs ≥8mm
Time frame: up to 4 weeks
mm^3
Time frame: up to 4 weeks
yes/no
Time frame: up to 4 weeks after inclusion
mmHg
Time frame: up to 4 weeks after inclusion
mmHg
Time frame: up to 4 weeks after inclusion
mmHg
Time frame: up to 4 weeks after inclusion
mmHg
Time frame: up to 4 weeks after inclusion
Time frame: up to 4 weeks
mmHg
Time frame: up to 4 weeks after inclusion
mmHg
Time frame: up to 4 weeks after inclusion
mmHg
Time frame: up to 4 weeks after inclusion
mmHg
Time frame: up to 4 weeks after inclusion
mmHg
Time frame: up tp 4 weeks
half-life of the tracer o0ver the convexities (minutes)
Time frame: up to 6 weeks
epidural membranes (descriptive) arachnoid funnels (descriptive) diverticula (descriptive) epidural vessels (descriptive)
Time frame: up to 4 weeks
cm/s
Time frame: up to 4 weeks
ml
Time frame: up to 4 weeks
mm
Time frame: up to 4 weeks
cm/s
Time frame: up to 4 weeks
Time frame: up to 4 weeks
Time frame: 4 weeks and 3 month after treatment
Rebound hypertension, Reoccurrence of the leak, Suture insufficiency, Bleeding, Sensory deficits, Motor deficits, Gait ataxia, Bladder dysfunction, Bowl dysfunction, Others
Time frame: 4 weeks after treatment
days
Time frame: 4 weeks after treatment
mean mg/d
Time frame: 3 months after treatment
range 0 to 9, 9 indicating highest likelihood of spinal CSF leak
Time frame: 3 months after treatment
Time frame: 3 months after treatment
yes /no
Time frame: 3, 6, 12 & 24 months after treatment
range 36 to 78 points, 78 indicating highest impact of headaches
Time frame: 3, 6, 12, & 24 months after treatment
<0 to1, 1indicating unimpaired health
Time frame: 3, 6, 12 & 24 months after treatment
range 7 to 42, 7 indicating highest improvement
Time frame: 12 & 24 months after treatment
range 0 to 39, 0 indicating lowest burden
Time frame: at 4 weeks & 3, 6, 12 & 24 months
range 0 to 5, 0 indicating full capacity
Time frame: 4 week, 3, 6, 12 & 24 months
Time frame: 4 week, 3, 6, 12 & 24 months
range 0 to 10, 10 indicating most severe pain
Time frame: 4 weeks, 3, 6, 12, 24 months
with headaches with pain medication intake in the last month
Time frame: 4 weeks, 3, 6, 12 & 24 months
hours
Time frame: 4 weeks, 3, 6, 12 &24 months
Time frame: 4 weeks, 3, 6, 12 & 24 months
in 0 to 10, 10 being most severe
Time frame: 4 weeks, 3, 6, 12 & 24 months
in 0 to 10, 10 being most severe
Time frame: 4 weeks, 3, 6, 12 & 24 months
in 0 to 10, 10 being most severe
Time frame: 4 weeks, 3, 6, 12 & 24 months
in 0 to 10, 10 being most severe
Time frame: 4 weeks, 3, 6, 12 & 24 months
in 0 to 10, 10 being most severe
Time frame: 4 weeks, 3, 6,12 &24 months
rated between 0 to 5, with 5 indicating highest burden
Time frame: 4 weeks, 3, 6, 12 & 24 months
rated between 0 to 5, with 5 indicating highest burden
Time frame: up to 6 months after treatment
cm/s
Time frame: up to 6 months after treatment
ml
Time frame: up to 6 months after treatment
mm
Time frame: up to 6 months after treatment
cm/s
Contact information is provided by the study sponsor or research team.
Florian Volz, Dr. med.
CONTACT
Katharina Wolf, Dr. med.
CONTACT
University Hospital Freiburg
Other
Acronym: SEAL
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07411690
Astrocytoma, Brain Diseases
Warsaw, Poland
View Trial DetailsNCT07216157
Brain Diseases, Brain Neoplasms
Warsaw, Poland
View Trial DetailsNCT01855425
CerebroSpinal Fluid (CSF) Leak, Cholesteatoma
Baltimore, Maryland, United States
View Trial DetailsNCT07614399
Brain Diseases, CSF Circulation Disorder
Prague, Czechia
View Trial Details